402 related articles for article (PubMed ID: 29361245)
21. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
[TBL] [Abstract][Full Text] [Related]
22. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
[No Abstract] [Full Text] [Related]
23. Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading.
Liu HS; Chiang SW; Chung HW; Tsai PH; Hsu FT; Cho NY; Wang CY; Chou MC; Chen CY
Comput Methods Programs Biomed; 2018 Mar; 155():19-27. PubMed ID: 29512499
[TBL] [Abstract][Full Text] [Related]
24. The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging.
Jia ZZ; Gu HM; Zhou XJ; Shi JL; Li MD; Zhou GF; Wu XH
Eur J Radiol; 2015 Sep; 84(9):1805-9. PubMed ID: 26066470
[TBL] [Abstract][Full Text] [Related]
25. Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.
Conte GM; Altabella L; Castellano A; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Caulo M; Falini A; Anzalone N
Eur Radiol; 2019 Jul; 29(7):3467-3479. PubMed ID: 30972545
[TBL] [Abstract][Full Text] [Related]
26. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
[TBL] [Abstract][Full Text] [Related]
27. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
28. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
[TBL] [Abstract][Full Text] [Related]
29. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading.
Su CQ; Lu SS; Han QY; Zhou MD; Hong XN
Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590
[TBL] [Abstract][Full Text] [Related]
30. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
31. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study.
Di N; Cheng W; Jiang X; Liu X; Zhou J; Xie Q; Chu Z; Chen H; Wang B
J Neuroradiol; 2019 May; 46(3):186-192. PubMed ID: 29752976
[TBL] [Abstract][Full Text] [Related]
32. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic Value of Combining Permeability with T1 Perfusion Parameters in Quantitative Dynamic Contrast-enhanced Magnetic Resonance Imaging for Glioma Grading].
Sun SJ; Qian HF; Li FQ; Li ZY; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):674-80. PubMed ID: 26725390
[TBL] [Abstract][Full Text] [Related]
34. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
35. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
36. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
[TBL] [Abstract][Full Text] [Related]
37. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
38. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach.
Falk A; Fahlström M; Rostrup E; Berntsson S; Zetterling M; Morell A; Larsson HB; Smits A; Larsson EM
Neuroradiology; 2014 Dec; 56(12):1031-8. PubMed ID: 25204450
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
[TBL] [Abstract][Full Text] [Related]
40. DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma.
Shin KE; Ahn KJ; Choi HS; Jung SL; Kim BS; Jeon SS; Hong YG
Clin Radiol; 2014 Jun; 69(6):e264-72. PubMed ID: 24594379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
